Clinical efficiency and safety of DC-CIK cells combined with conventional chemotherapy in treatment of advanced non small cell lung cancer

doi:10.3969/j.issn.1002-7386.2016.19.004

Abstract：Objective To analyze the clinical efficiency and safety of DC-CIK cells combined with conventional chemotherapy in treatment of advanced non small cell lung cancer ( NSCLC) .Methods Eighty-one patients with NSCLC who were admitted and treated in Department of Oncology of our hospital from January 2010 to October were enrolled in the study. According to different therapy modes,these patients were divided into observation group ( n =40 ) and control group ( n =41).The patients in observation group were treated by NP chemotherapy combined with DC-CIK cells,however,the patients in control group were treated by NP chemotherapy only.The therapeutic effects, performance status ( Karnofsky score ) , changes of immune function, blood routine test, liver and kidney function, adverse reactions, survival status were observed and compared between two groups.Results The total effective rate in observation group and control group was 37.50% and 29.27%,respectively, there was no significant difference between two groups (χ2 =1.468, P >0.05).The disease control rate and total improvement rate of physical state in observation group was 87.50%, 90.00%, respectively, which was significantly higher than that (75.61%, 73.1%, respectively) in control group( P<0.05).Until the end of follow up, among 40 patients in observation group,30 patients died and 10 patients survived in whom the median carcinoma -free survival time was7.5 months, and the median survival time was 14.5 months, however, among 41 patients in control group,35 patients died,6 patients survived in whom the median carcinoma-free survival time was 4.5 months, the median survival time was 11.5 months.Log-rank detection showed that the median carcinoma-free survival time in observation group was significant longer than that in control group (χ2 =6.557, P <0.05),moreover, the median survival time in observation group was longer than that in control group,but there was no significant difference between two groups (χ2 =1384, P >0.05).Before treatment there was no significant difference in the positive percentage of CD 3+,CD 8+,CD 5+6 in peripheral blood T lymphocyte between two groups ( P <0.05).After treatment the positive percentage of CD 3+,CD 8+,CD 5+6 in observation group was significantly higher than that before treatment ( P <0.05 ) , however the positive percentage of CD3+, CD8+, CD5+6 in control group was significantly lower than that before treatment ( P <0.05).After treatment the positive percentage of CD3+,CD8+,CD5+6 in observation group was significantly higher than that in control group ( P <0.05).The fever rate in observation group was significantly higher than that in control group (χ2 =6.549, P <0.05).There were no significant differences in incidence rates of leukopenia, thrombocytopenia, hair loss, digestive tract reaction, hepatic function impairment, renal function impairment between two groups ( P <0.05) .Moreover the adverse reactions were slight in both groups .Conclusion DC-CIK cells combined with conventional chemotherapy is a safe and effective treatment manner for patients with advanced NSCLC.